GlaxoSmithKline gets US FDA approval for Boostrix to prevent tetanus, diphtheria and pertussis in older people

11 July 2011

The US Food and Drug Administration on Friday approved the use of UK pharma giant GlaxoSmithKline’s (LSE: GSK) Boostrix vaccine to prevent tetanus, diphtheria and pertussis (whooping cough) in people aged 65 and older.

Currently, there are vaccines approved for the prevention of tetanus and diphtheria that can be used in adults 65 and older. However, Boostrix, which is given as a single-dose booster shot, is the first vaccine approved to prevent all three diseases in older people, the FDA noted.

Boostrix, which generated revenues of £181 million ($290 million) last year, was originally approved in the USA in May 2005, for use in adolescents aged 10 years through 18 years. It subsequently gained clearance in December 2008, to include adults 19 years through 64 years. Boostrix is manufactured by GlaxoSmithKline Biologicals, based in Rixensart, Belgium.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK